[Experimental and initial clinical experiences with the new class Ib anti-arrhythmia agent barucainide].
Barucainide is a new class Ib-antiarrhythmic compound which causes a reduction of the upstroke velocity and shortens the duration of the action potential in a dose-dependent fashion. The electrophysiological, hemodynamic and antiarrhythmic effects of the new drug were analyzed in experimental and clinical investigations. The results show that barucainide, in a dose range varying between 0.125-4.0 mg/kg i.v. fails to exert any significant effect on cardiac conduction and refractory times, heart rate, arterial blood pressure, cardiac output and left ventricular contractility. In a standardized animal model of ventricular arrhythmia, barucainide proved to be superior to lidocaine with respect to its antiarrhythmic potency. In a group of patients displaying chronic, otherwise therapy-resistant ventricular arrhythmias, the drug was effective in the majority of cases. Tolerance was excellent over a maximum observation period of 18 months. According to our first experimental and clinical observations, further testing of barucainide appears promising. The drug may be of particular value for treatment of ventricular arrhythmias in cases with left ventricular dysfunction, heart failure and severe conduction disturbances.